BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 7913936)

  • 1. Frequent RET protooncogene mutations in multiple endocrine neoplasia type 2A.
    Quadro L; Panariello L; Salvatore D; Carlomagno F; Del Prete M; Nunziata V; Colantuoni V; Di Giovanni G; Brandi ML; Mannelli M
    J Clin Endocrinol Metab; 1994 Aug; 79(2):590-4. PubMed ID: 7913936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P
    Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The RET protooncogene in sporadic pheochromocytomas: frequent MEN 2-like mutations and new molecular defects.
    Beldjord C; Desclaux-Arramond F; Raffin-Sanson M; Corvol JC; De Keyzer Y; Luton JP; Plouin PF; Bertagna X
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2063-8. PubMed ID: 7608256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.
    Eng C; Smith DP; Mulligan LM; Nagai MA; Healey CS; Ponder MA; Gardner E; Scheumann GF; Jackson CE; Tunnacliffe A
    Hum Mol Genet; 1994 Feb; 3(2):237-41. PubMed ID: 7911697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group.
    Frank-Raue K; Höppner W; Frilling A; Kotzerke J; Dralle H; Haase R; Mann K; Seif F; Kirchner R; Rendl J; Deckart HF; Ritter MM; Hampel R; Klempa J; Scholz GH; Raue F
    J Clin Endocrinol Metab; 1996 May; 81(5):1780-3. PubMed ID: 8626834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A.
    Berndt I; Reuter M; Saller B; Frank-Raue K; Groth P; Grussendorf M; Raue F; Ritter MM; Höppner W
    J Clin Endocrinol Metab; 1998 Mar; 83(3):770-4. PubMed ID: 9506724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
    Sansó G; Domené HM; Iorcansky S; Barontini M
    Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in the RET protooncogene in sporadic pheochromocytomas.
    Lindor NM; Honchel R; Khosla S; Thibodeau SN
    J Clin Endocrinol Metab; 1995 Feb; 80(2):627-9. PubMed ID: 7852530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular analysis of the RET proto-oncogene in patients with sporadic medullary thyroid carcinoma: a novel point mutation in the extracellular cysteine-rich domain.
    Bugalho MJ; Frade JP; Santos JR; Limbert E; Sobrinho L
    Eur J Endocrinol; 1997 Apr; 136(4):423-6. PubMed ID: 9150704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple endocrine neoplasia type 2A with the identical somatic mutation in medullary thyroid carcinoma and pheochromocytoma without germline mutation at the corresponding site in the RET proto-oncogene.
    Akama H; Noshiro T; Kimura N; Shimizu K; Watanabe T; Shibukawa S; Nakai S; Miura W; Ito S; Miura Y
    Intern Med; 1999 Feb; 38(2):145-9. PubMed ID: 10225670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RET proto-oncogene point mutations in sporadic neuroendocrine tumors.
    Komminoth P; Roth J; Muletta-Feurer S; Saremaslani P; Seelentag WK; Heitz PU
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2041-6. PubMed ID: 8964826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.
    Romei C; Elisei R; Pinchera A; Ceccherini I; Molinaro E; Mancusi F; Martino E; Romeo G; Pacini F
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1619-22. PubMed ID: 8636377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type.
    Uchino S; Noguchi S; Yamashita H; Sato M; Adachi M; Yamashita H; Watanabe S; Ohshima A; Mitsuyama S; Iwashita T; Takahashi M
    Jpn J Cancer Res; 1999 Nov; 90(11):1231-7. PubMed ID: 10622534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-specific mutations in the tyrosine kinase domain of the RET proto-oncogene in pheochromocytomas of sporadic type.
    Yoshimoto K; Tanaka C; Hamaguchi S; Kimura T; Iwahana H; Miyauchi A; Itakura M
    Endocr J; 1995 Apr; 42(2):265-70. PubMed ID: 7627271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single missense mutation in codon 918 of the RET proto-oncogene in sporadic medullary thyroid carcinomas.
    Maeda S; Namba H; Takamura N; Tanigawa K; Takahashi M; Noguchi S; Nagataki S; Kanematsu T; Yamashita S
    Endocr J; 1995 Apr; 42(2):245-50. PubMed ID: 7627269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B.
    Carlson KM; Dou S; Chi D; Scavarda N; Toshima K; Jackson CE; Wells SA; Goodfellow PJ; Donis-Keller H
    Proc Natl Acad Sci U S A; 1994 Feb; 91(4):1579-83. PubMed ID: 7906417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Detection of RET-proto-oncogene mutations in the diagnosis of Type 2 endocrine neoplasia (MEN 2)].
    Komminoth P; Muletta-Feurer S; Soltermann A; Gemsenjäger E; Bürgi H; Staub JJ; Schönle E; Fried M; Vetter W; Spinas GA; Heitz PU
    Schweiz Med Wochenschr; 1996 Aug; 126(31-32):1329-38. PubMed ID: 8765374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma.
    Hofstra RM; Landsvater RM; Ceccherini I; Stulp RP; Stelwagen T; Luo Y; Pasini B; Höppener JW; van Amstel HK; Romeo G
    Nature; 1994 Jan; 367(6461):375-6. PubMed ID: 7906866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A.
    Vieira AE; Mello MP; Elias LL; Lau IF; Maciel LM; Moreira AC; Castro M
    Horm Metab Res; 2002 Apr; 34(4):202-6. PubMed ID: 11987030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.
    Donis-Keller H; Dou S; Chi D; Carlson KM; Toshima K; Lairmore TC; Howe JR; Moley JF; Goodfellow P; Wells SA
    Hum Mol Genet; 1993 Jul; 2(7):851-6. PubMed ID: 8103403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.